Checked 2026-11-10. Independent clinical review has not been completed. WADAFUK is independent of WADA and does not provide medical advice or an individual anti-doping determination.
Prohibited at all times
2026: prohibited at all times (S2). [1]
2026 List, S2.2.4, printed page 8 · 2026 rules apply from 1 January 2026. Any 2027 material below concerns future rules from 1 January 2027; it is not current clearance.
Identity and research setting
Ipamorelin is a synthetic pentapeptide that acts at the ghrelin receptor and can stimulate growth-hormone release. Free-base and acetate preparations require their own identity assessment. Its clinical research includes postoperative gastrointestinal recovery, which is different from wellness or athletic use. [2]
Postoperative trial
A randomized, multicentre, blinded, placebo-controlled proof-of-concept study enrolled 117 people after bowel resection; 114 were included in the safety and modified intention-to-treat analyses. It did not show a significant improvement in the primary solid-meal-tolerance endpoint or secondary endpoints. The abstract therefore does not establish faster postoperative recovery, let alone benefit in healthy athletes. [3]
- Primary trial access was limited to the author-institution abstract.
Safety and marketing
FDA’s review describes serious postoperative complications, including deaths, with uncertain attribution to ipamorelin. It also discusses glucose and potassium abnormalities and peptide-quality or immune-reaction concerns. These findings cannot establish either that the compound caused every event or that it is safe. [2]
FDA found inadequate support for advertised wellness uses and for generalizing to subcutaneous products. Standalone or blended products marketed with CJC-1295 are not validated by the hospital trial. The staff review is scientific advice, not a current universal legal ruling. [2]
What remains uncertain
- Full primary trial safety tables were not independently read.
- No long-term wellness-use, athletic-performance or product-assay evidence was verified.
Check the sources.
These are concise editorial paraphrases of selected sources, not a systematic review or a reproduction of source tables. Access depth is shown for each reference; an abstract-only check cannot resolve details found only in a full paper.
- WADA 2026 Prohibited List ↗Accessed 2026-11-10 · official_full_text_relevant_sections
Effective date; S0 printed page 4; S2 printed pages 7–8
- FDA staff review: ipamorelin related substances, 19 August 2024 ↗Accessed 2026-11-10 · official_full_text_relevant_sections
Identity, safety and effectiveness; postoperative adverse-event narrative
- Beck et al. 2014: ipamorelin after bowel resection ↗Accessed 2026-11-10 · abstract_only
USU institutional abstract; DOI 10.1007/s00384-014-2030-8
Check the current official WADA List and the relevant anti-doping authority for your sport, product, route and circumstances. Do not stop or change necessary treatment based on this page. Ask a qualified clinician about health decisions. Missing evidence does not establish safety.